论文部分内容阅读
通常,对于慢性活动性乙型肝炎无法治疗,但是,从α1胸腺素的临床研究所得的初步资料提示这种正在被Alphal生物医学公司(在华盛顿特区)研制的肽,可以治疗这种疾病。根据正在指导这项试验的Wayne州立大学的Milton Mutchnick说,在接受这种肽的5名病人中,两种与肝脏损害有关系的酶:SGPT和SGOT,已降至正常水平。4名对照病人中只有一人有这种变化,而且,在80％受治疗的病人中的乙型肝炎病毒DNA已消除,并且该病的另一种标志E抗原也消失了。只有25％的对照组的这种病毒DNA消失,E抗原均未消失。
Often, chronic active hepatitis B can not be treated, however, preliminary data from clinical studies of alpha1 thymosins suggest that this peptide, being developed by Alphal Biomedical (in Washington, DC), can treat this condition. According to Milton Mutchnick of Wayne State University who is guiding the trial, two of the five patients who received this peptide had reduced levels of normalized SGPT and SGOT enzymes: SGPT and SGOT. Only one out of four control patients had such a change and, in 80% of treated patients, hepatitis B virus DNA had been eliminated and another sign of the disease, the E antigen, disappeared. Only 25% of the control group of this virus DNA disappeared, E antigen did not disappear.